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Dear Editor
Tumor Necrosis Factor-a (TNF-a) inhibitors, 
in particular infliximab, have shown effective-
ness as a third-line treatment option in relapsing, 
refractory sarcoidosis that requires an increased 
dose of corticosteroids plus one or more anti-sar-
coidosis disease modifying drugs [1]. Infliximab 
has demonstrated effectiveness in severe pulmo-
nary sarcoidosis and in extra-pulmonary sarcoid-
osis with multi-organ involvement. Bone involve-
ment is reported to occur in 5-13% of patients at 
some point during their chronic disease course. 
Recently, in a study of 64 sarcoidosis patients, 
Zhou et al. found that bone disease occurs mainly 
in white females with chronic multi-organ dis-
ease. This bone involvement most commonly af-
fects the spine (68.8%), pelvis (35.9%), and hands 
(15.6%). These patients are chronically treated 
with corticosteroids and almost a quarter of them 
(23.5%) received infliximab, which appears to be 
beneficial in chronic bone sarcoidosis [2]. 
In this article, we report on a case of a 68-year-
old Caucasian female with chronic active sarcoid-
osis which had pulmonary, cutaneous, and joint 
involvement. The patient also had an unbalanced 
calcium metabolism. Physical examination of the 
hands exhibited severe dactylitis (purple-violet 
discoloration, swelling, distortion, pain, numb-
ness, and nail dystrophy). Due to the relapsing na-
ture of her disease, significant arthralgia after the 
tapering of pharmacological therapy (prednisone 
below 15mg in combination with leflunomide 
20mg/d), and significant side-effects (osteoporo-
sis), she was started on infliximab 5mg/kg. She 
received 6 doses of infliximab during a 6 month 
period (at 0, 2, 6, 12, 18, and 24 weeks, respective-
ly). At the end of the 6 months of treatment, the 
patient showed significant clinical improvement 
with complete resolution of her arthritis. Angio-
tensin-converting enzyme levels fell from 110 U/l 
to 58 U/l. However, shortly before the last inflix-
imab infusion, she developed an erythematous, 
patchy, and painful cutaneous lesion located 
unilaterally and affecting the dorsal, lateral, and 
phalangeal skin surface of the right lower foot 
(Figure 1A). The lesion was biopsied and a histo-
pathological examination revealed erythema mul-
tiforme (EM) (Figure 1B). Since the patient had not 
received any other medications which had been 
known to cause EM, and all cultures and tests for 
viruses, fungi, and microbes were negative, this 
was considered to be an infliximab-related infu-
sion reaction resulting in erythema multiforme. 
After the 6th infusion, infliximab was withdrawn 
(as initially planned) and EM gradually subsided 
without any other intervention. 
In two recently published studies focusing 
on refractory sarcoidosis patients with cutaneous 
symptoms, French investigators treating these 
patients with anti-TNF-a agents reported dis-
continuation rates due to adverse effects of 24% 
and 23%, respectively [3, 4]. Notable side effects 
that necessitated withdrawing treatment with 
anti-TNF-a agents included infections and serious 
immunological reactions. On the other hand, cu-
taneous reactions stemming from the use of these 
agents are described to occur commonly (up to 
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25%) in patients treated for rheumatologic con-
ditions and inflammatory bowel diseases. Such 
reactions include psoriasis, xerosis, eczema, skin 
infections, skin cancer, palmoplantar pustulosis, 
alopecia areata, bullous pemphigoid, drug-in-
duced lupus, and urticaria [5, 6]. However, EM 
due to infliximab is rare. Although a 2009 Food 
and Drug Administration (FDA) report included 
infliximab cutaneous adverse events, only 21 such 
cases have been reported and all were related to 
rheumatologic conditions [7, 8]. This case is the 
first to our knowledge to describe EM after therapy 
with infliximab in a patient with sarcoidosis.
Cutaneous involvement in sarcoidosis is 
frequent, affecting up to 25% of patients at some 
point in their disease course. In our patient, 
the differential diagnosis included specific or 
non-specific cutaneous sarcoidosis involvement, 
skin infections, drug-related reactions, and para-
doxical sarcoid-like reactions (reported mainly 
with use of etanercept in rheumatoid arthritis 
and inflammatory bowel diseases) [9]. The up-
dated ACCESS organ assessment tool classified 
our patient`s skin lesions as possibly being due 
to sarcoidosis because of their atypical nature, 
therefore, histologic confirmation was mandatory 
[10]. Since no granulomas were discovered and 
a temporal association with infliximab admini-
stration existed, we considered this EM to be 
infliximab-related.  
Infliximab-induced EM may warrant drug 
interruption or discontinuation. Therefore, it is 
important to consider infliximab-induced EM in 
the differential diagnosis. This would have signi-
ficant implications for the patient because it could 
lead to avoiding unnecessary treatment escalation 
for presumed treatment failure and allowing for 
appropriate local or systemic EM therapy as well 
as, if necessary, changing the treatment. In our 
case, tapering infliximab resulted in EM resolution. 
Corticosteroids (prednisone) were successfully ta-
pered to a dose of 7.5 mg. The patient also received 
leflunomide. The patient has remained stable for 
18 months without the need to introduce another 
mode of pharmacological treatment.
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Figure 1. A. Patchy erythematous lesions of the right lower foot at the resolution phase after infliximab discontinuation. B. Erythema multiforme: 
Intraepidermal edema with liquefactive necrosis (double thick arrow), lymphocytic exocytosis (simple arrows), spongiosis (simple thick arrow), 
dyskeratotic cells, and dermal inflammatory infiltrate including lymphocytes and histiocytes (double thin arrow) (Hematoxylin-Eosin stain X100)
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